Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

Inhibitors of poly(ADP-ribose) polymerase (PARP)-mediated DNA repair have shown promise in early clinical studies in the treatment of specific subgroups of breast cancer. Notably, phase II trials indicate that olaparib, an oral PARP inhibitor, has activity as a single agent in BRCA-related tumours,...

Descripción completa

Detalles Bibliográficos
Autor principal: Plummer, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236327/
https://www.ncbi.nlm.nih.gov/pubmed/21884642
http://dx.doi.org/10.1186/bcr2877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236327/
https://www.ncbi.nlm.nih.gov/pubmed/21884642
http://dx.doi.org/10.1186/bcr2877

Ejemplares similares